LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

17.25 0.76

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.1

Max

17.3

Galvenie mērījumi

By Trading Economics

Ienākumi

-70M

-67M

Pārdošana

-2.1M

20M

P/E

Sektora vidējais

48.528

79.874

Dividenžu ienesīgums

0.48

Peļņas marža

-330.585

Darbinieki

243

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-6.6% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.31%

Nākamie ieņēmumi

2025. g. 1. dec.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-5.6M

346M

Iepriekšējā atvēršanas cena

16.49

Iepriekšējā slēgšanas cena

17.25

Ziņu noskaņojums

By Acuity

17%

83%

163 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 27. nov. 16:49 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

2025. g. 27. nov. 15:32 UTC

Iegādes, apvienošanās, pārņemšana

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

2025. g. 27. nov. 23:50 UTC

Tirgus saruna

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

2025. g. 27. nov. 23:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 27. nov. 16:05 UTC

Tirgus saruna

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

2025. g. 27. nov. 16:04 UTC

Tirgus saruna

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

2025. g. 27. nov. 15:54 UTC

Iegādes, apvienošanās, pārņemšana

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

2025. g. 27. nov. 15:44 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: No Certainty Talks Will Result in Transaction

2025. g. 27. nov. 15:43 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

2025. g. 27. nov. 15:42 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

2025. g. 27. nov. 15:41 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

2025. g. 27. nov. 15:11 UTC

Tirgus saruna

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

2025. g. 27. nov. 14:26 UTC

Tirgus saruna

Hermes' Outperformance Gap Could Narrow -- Market Talk

2025. g. 27. nov. 14:11 UTC

Tirgus saruna

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

2025. g. 27. nov. 14:11 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 27. nov. 13:35 UTC

Tirgus saruna

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

2025. g. 27. nov. 13:33 UTC

Tirgus saruna

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

2025. g. 27. nov. 13:22 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 27. nov. 13:22 UTC

Tirgus saruna

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

2025. g. 27. nov. 13:17 UTC

Tirgus saruna

LVMH Should Be Able to Recover Next Year -- Market Talk

2025. g. 27. nov. 11:13 UTC

Tirgus saruna

European Gas Prices Come Under Pressure -- Market Talk

2025. g. 27. nov. 11:07 UTC

Peļņas

Genting: Positive About Prospects Over Longer Term

2025. g. 27. nov. 11:06 UTC

Peļņas

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

2025. g. 27. nov. 11:04 UTC

Peļņas

Genting: International Travel Demand Expected to Remain Resilient

2025. g. 27. nov. 11:04 UTC

Peļņas

Genting: Global Growth Expected to Remain Subdued

2025. g. 27. nov. 11:04 UTC

Peļņas

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

2025. g. 27. nov. 10:59 UTC

Peļņas

Genting Bhd 3Q Net Profit Fell 86% on Year

2025. g. 27. nov. 10:58 UTC

Peļņas

Genting Bhd 3Q Rev Rose 14% on Year

2025. g. 27. nov. 10:56 UTC

Peļņas

Genting Bhd 3Q Net MYR30.3M

2025. g. 27. nov. 10:56 UTC

Peļņas

Genting Bhd 3Q EPS MYR0.0079

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-6.6% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD  -6.6%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

163 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat